Results 81 to 90 of about 558 (131)
Molecular response with asciminib 20 mg QD in a patient intolerant to multiple TKIs. [PDF]
Ann HematolStuckey R, Navarrete Bullón L, Borrero Borrego A, Vidal Ballester V, Rodríguez-Medina C, Morales Curbelo A, González Pinedo L, Torres Ochando M, Veiga Vaz A, Perera MDM, Bilbao-Sieyro C, López Rodríguez JF, Segura-Díaz A, Gómez-Casares MT. +13 moreeuropepmc +1 more sourceAdult patients with autoinflammation of unknown origin partially phenocopy the immune presentation of Still's disease. [PDF]
Nat CommunVeiga R, De Vuyst L, Poulet C, Neumann J, Bücken L, Prezzemolo T, Willemsen M, Vanderschueren S, Matthys P, Chabaane E, Fléron M, Cobraiville G, Baiwir D, Mazzucchelli G, Immunome Project Consortium for Autoinflammatory Disorders (ImmunAID), Fautrel B, Wouters C, De Seny D, Humblet-Baron S, Liston A. +19 moreeuropepmc +1 more sourceAlterations in p53, Microsatellite Stability and Lack of MUC5AC Expression as Molecular Features of Colorectal Carcinoma Associated with Inflammatory Bowel Disease. [PDF]
Int J Mol Sci, 2023 Gené M, Cuatrecasas M, Amat I, Veiga JA, Fernández Aceñero MJ, Fusté Chimisana V, Tarragona J, Jurado I, Fernández-Victoria R, Martínez Ciarpaglini C, Alenda González C, Zac C, Ortega de la Obra P, Fernández-Figueras MT, Esteller M, Musulen E. +15 moreeuropepmc +1 more sourceNo Evidence that <i>CD33</i> rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group. [PDF]
Dis Markers, 2022 Castaño-Bonilla T, Barragán E, Sargas C, Sanz A, Algarra L, Herrera-Puente P, García-Boyero R, Barrios M, Martinez-Cuadron D, Rodriguez-Veiga R, Boluda B, Gil C, Serrano-López J, Martínez-López J, Martínez-López J, Sayas-Lloris MJ, Olave MT, Riaza-Grau R, Castillo TB, Larrayoz MJ, Amigo R, Jiménez-Velasco A, Sánchez J, Ayala R, Blas C, Lainez D, Serrano-López J, Sanz MA, Alonso-Domínguez JM, Montesinos P. +29 moreeuropepmc +1 more sourceInfluence of expanded graphene on physical and chemical properties, and <i>in vitro</i> toxicity of glass ionomer cements for luting. [PDF]
Biomater Investig DentMartins SP, Geraldino Monteiro CM, da Silva RR, Pintor AVB, Magno MB, Visconti MA, Villela Romanos MT, de Menezes LR, Maia LC, Pithon MM. +9 moreeuropepmc +1 more sourceHealthcare Resource Utilization and Treatment Costs for Blastic Plasmacytoid Dendritic Cell Neoplasm: A PETHEMA Study. [PDF]
Cancers (Basel)Solana-Altabella A, Navarro-Vicente I, Rodríguez-Arbolí E, Noriega V, Serrano J, Bernal T, Carrasco-Baraja V, Garcia-Boyero R, Olivier Cornacchia C, Algarra L, López-Briz E, Mena-Durán A, Solano-Tovar J, Botella-Prieto C, Sánchez-Sánchez S, Bergua-Burgues JM, Lloret-Madrid P, Rodenas-Rovira M, Boluda B, Cano-Ferri I, Acuña-Cruz E, Rodríguez-Veiga R, Torres-Miñana L, Centelles-Oria M, Poveda-Andrés JL, Martínez-Cuadrón D, Montesinos P. +26 moreeuropepmc +1 more sourceRetraction Note: Antibodies against endogenous retroviruses promote lung cancer immunotherapy. [PDF]
NatureNg KW, Boumelha J, Enfield KSS, Almagro J, Cha H, Pich O, Karasaki T, Moore DA, Salgado R, Sivakumar M, Young G, Molina-Arcas M, de Carné Trécesson S, Anastasiou P, Fendler A, Au L, Shepherd STC, Martínez-Ruiz C, Puttick C, Black JRM, Watkins TBK, Kim H, Shim S, Faulkner N, Attig J, Veeriah S, Magno N, Ward S, Frankell AM, Al Bakir M, Lim EL, Hill MS, Wilson GA, Cook DE, Birkbak NJ, Behrens A, Yousaf N, Popat S, Hackshaw A, TRACERx Consortium, CAPTURE Consortium, Hiley CT, Litchfield K, McGranahan N, Jamal-Hanjani M, Larkin J, Lee SH, Turajlic S, Swanton C, Downward J, Kassiotis G. +50 moreeuropepmc +1 more source
